Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.720
-0.050 (-1.81%)
Aug 14, 2025, 9:25 AM - Market open
BDTX Employees
Black Diamond Therapeutics had 24 employees as of December 31, 2024. The number of employees decreased by 30 or -55.56% compared to the previous year.
Employees
24
Change (1Y)
-30
Growth (1Y)
-55.56%
Revenue / Employee
$2,916,667
Profits / Employee
$601,625
Market Cap
154.86M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BDTX News
- 7 days ago - Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside - Seeking Alpha
- 2 months ago - Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha
- 5 months ago - Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy - GlobeNewsWire
- 5 months ago - Black Diamond Therapeutics: In Decline, But Why? - Seeking Alpha